Ticker Details
Intellia Therapeutics, Inc. Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.
IPO Date:	May 6, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.8B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.18 | 3.58%
Avg Daily Range (30 D):	$0.42 | 3.46%
Avg Daily Range (90 D):	$0.52 | 3.76%

Institutional Daily Volume
Avg Daily Volume:	1.46M
Avg Daily Volume (30 D):	3.36M
Avg Daily Volume (90 D):	5.12M

Trade Size
Avg Trade Size (Sh.):	81
Avg Trade Size (Sh.) (30 D):	88
Avg Trade Size (Sh.) (90 D):	96

Institutional Trades
Total Institutional Trades:	5,228
Avg Institutional Trade:	$2.99M
Avg Institutional Trade (30 D):	$3.19M
Avg Institutional Trade (90 D):	$3.77M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$4.99M
Avg Closing Trade (30 D):	$5.34M
Avg Closing Trade (90 D):	$8.77M
Avg Closing Volume:	186.35K

News

Jul 3, 2026 @ 8:44 AM Gene Editing Therapeutics: Transforming Biopharmac... Source: Researchandmarkets.Com

Jul 3, 2026 @ 8:41 AM Global CRISPR-Based Drug Development Platforms Mar... Source: Researchandmarkets.Com

Jun 24, 2026 @ 8:03 AM Wall Street Expects This Growth Stock That's Alrea... Source: Adria Cimino

Jun 20, 2026 @ 3:02 PM Intellia Therapeutics vs. Omeros: Which Emerging B... Source: Brendan Coffey

Jun 17, 2026 @ 6:30 AM This Stock Is Up 58% This Year. Is It too Late to ... Source: Prosper Junior Bakiny

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-3.35	$-.8	$-.81
Diluted EPS	$-3.35	$-.8	$-.81
Revenue	$59.51M	$7.66M	$15.05M
Gross Profit
Net Income / Loss	$-399.98M	$-106.63M	$-96.23M
Operating Income / Loss	$-423.48M	$-112.76M	$-100.53M
Cost of Revenue
Net Cash Flow	$-48.59M	$-28.57M	$-17.47M
PE Ratio